Hologic Inc Stock Research

Market Summary

USD79.61+0.41

Delayed

0.52%

HOLX Alerts

Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)

HOLX Stock Price

HOLX RSI Chart

HOLX Valuation

Market Cap

19.7B

Price/Earnings (Trailing)

19.88

Price/Sales (Trailing)

4.41

EV/EBITDA

14.41

Price/Free Cashflow

11.29

HOLX Price/Sales (Trailing)

HOLX Profitability

EBT Margin

26.99%

Return on Equity

19.44%

Return on Assets

10.66%

Free Cashflow Yield

8.86%

HOLX Fundamentals

HOLX Revenue

Revenue (TTM)

4.5B

Revenue Y/Y

-26.98%

Revenue Q/Q

12.69%

HOLX Earnings

Earnings (TTM)

990.2M

Earnings Y/Y

-62.46%

Earnings Q/Q

57.88%

Price Action

52 Week Range

59.7886.65

(Low)(High)

Last 7 days

1.7%

Last 30 days

-0.6%

Last 90 days

5.1%

Trailing 12 Months

4.7%

HOLX Financial Health

Current Ratio

4.21

Debt/Equity

0.55

Debt/Cashflow

0.64

HOLX Investor Care

Buy Backs (1Y)

2.44%

Diluted EPS (TTM)

3.93

Peers (Alternatives to Hologic)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MDT	106.0B	30.8B	-4.61%	-26.01%	26.06	3.44	-3.19%	-17.38%
SYK	103.1B	18.4B	6.02%	5.19%	43.7	5.59	7.84%	18.25%
ISRG	88.4B	6.2B	9.31%	-11.96%	66.85	14.21	8.97%	-22.43%
BDX	68.6B	19.0B	2.19%	-5.22%	42.6	3.61	-0.43%	-8.78%
EW	49.2B	5.4B	6.12%	-27.99%	32.34	9.15	2.86%	1.25%
MID-CAP
SWAV	7.2T	489.7M	16.25%	13.06%	82.2K	16.8K	106.51%	2464.23%
PEN	10.4B	847.1M	3.66%	36.84%	-5.2K	12.31	13.32%	-137.89%
GMED	5.2B	1.0B	-9.17%	-24.82%	30.22	5.09	6.76%	24.45%
IRTC	3.6B	410.9M	3.83%	-15.78%	-30.64	8.66	27.29%	-14.60%
TNDM	2.7B	801.2M	11.07%	-63.68%	-28.28	3.34	14.00%	-707.69%
SMALL-CAP
SILK	1.6B	138.6M	-27.43%	0.81%	-28.66	11.37	36.62%	-10.44%
AVNS	1.3B	820.0M	0.91%	-12.65%	26.12	1.61	10.13%	701.59%
BLFS	895.1M	154.8M	-4.09%	4.51%	-8.6	5.78	60.29%	-2309.58%
CSII	828.4M	239.8M	0.81%	-4.01%	-21.88	3.45	-4.74%	-31.15%

Financials for Hologic

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-8.2%	4,466	4,863	5,226	5,392	5,494
Gross Profit	-12.3%	2,629	2,997	3,311	3,463	3,602
Operating Expenses	0.8%	1,368	1,357	1,372	1,429	1,366
S&GA Expenses	2.6%	647	630	630	621	581
R&D Expenses	0.7%	285	283	284	288	290
EBITDA	-21.4%	1,392	1,773	2,040	2,470	-
EBITDA Margin	-14.5%	0.31*	0.36*	0.39*	0.46*	-
Earnings Before Taxes	-24.1%	1,205	1,588	1,855	1,944	2,151
EBT Margin	-17.4%	0.27*	0.33*	0.36*	0.36*	-
Interest Expenses	2.5%	98.00	95.00	94.00	93.00	91.00
Net Income	-23.9%	990	1,302	1,512	1,552	1,716
Net Income Margin	-17.2%	0.22*	0.27*	0.29*	0.29*	-
Free Cahsflow	-15.1%	1,744	2,055	2,658	2,148	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	2.4%	9,290	9,071	9,357	9,515	9,285
Current Assets	4.1%	4,021	3,862	3,909	3,881	3,506
Cash Equivalents	4.4%	2,441	2,340	2,375	2,291	1,421
Inventory	8.7%	678	624	581	526	518
Net PPE	2.6%	494	482	490	507	554
Goodwill	1.6%	3,290	3,237	3,286	3,317	3,329
Current Liabilities	2.0%	956	938	1,001	1,305	1,279
Long Term Debt	0.0%	2,823	2,822	3,070	3,068	-
LT Debt, Current	37.3%	21.00	15.00	8.00	256	249
LT Debt, Non Current	-0.1%	2,806	2,808	2,815	2,813	2,820
Shareholder's Equity	4.4%	5,093	4,876	4,998	4,793	4,519
Retained Earnings	11.7%	1,788	1,600	1,482	1,253	798
Additional Paid-In Capital	0.3%	6,061	6,043	6,017	5,997	5,964
Shares Outstanding	-1.4%	247	251	252	253	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-14.6%	1,815	2,126	2,423	2,755	2,245
Share Based Compensation	2.7%	69.00	67.00	66.00	66.00	65.00
Cashflow From Investing	64.2%	-73.80	-206	-217	-965	-1,453
Cashflow From Financing	4.0%	-726	-756	-668	-318	-245
Buy Backs	-12.4%	475	542	367	555	476

Risks for HOLX

What is the probability of a big loss on HOLX?

53.5%

Probability that Hologic stock will be more than 20% underwater in next one year

19.2%

Probability that Hologic stock will be more than 30% underwater in next one year.

18.5%

Probability that Hologic stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HOLX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Hologic was unfortunately bought at previous high price.

Drawdowns

Returns for HOLX

Cumulative Returns on HOLX

13.4%

10-Year Cumulative Returns

12.7%

7-Year Cumulative Returns

16.3%

5-Year Cumulative Returns

33.8%

3-Year Cumulative Returns

What are the long-term rolling returns for HOLX?

FIve years rolling returns for Hologic.

Annualized Returns

Which funds bought or sold HOLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	ETF MANAGERS GROUP, LLC	sold off	-100	-166,000	-	-%
2023-03-23	MetLife Investment Management, LLC	reduced	-1.61	601,242	4,871,630	0.04%
2023-03-17	American Portfolios Advisors	added	2.09	-820	15,743	-%
2023-03-15	B. Riley Wealth Advisors, Inc.	reduced	-15.46	-6,248	264,752	0.01%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	21.28	111,820,000	387,094,000	0.42%
2023-03-06	OLD MISSION CAPITAL LLC	sold off	-100	-309,000	-	-%
2023-03-06	NORTH STAR ASSET MANAGEMENT INC	added	0.14	2,626,780	18,934,800	1.18%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-3.5	26,000	243,000	-%
2023-02-28	Voya Investment Management LLC	reduced	-16.28	-403,508	13,370,500	0.02%
2023-02-24	NATIXIS	added	238	3,236,520	4,344,520	0.02%

Latest Funds Activity

Are funds buying HOLX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own HOLX

No. of Funds

Hologic News

Schedule 13G FIlings of Hologic

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	t. rowe price investment management, inc.	9.5%	23,376,904	SC 13G
Feb 09, 2023	vanguard group inc	11.60%	28,519,496	SC 13G/A
Jan 24, 2023	blackrock inc.	9.6%	23,478,641	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	16.4%	41,296,661	SC 13G/A
Feb 10, 2022	vanguard group inc	10.94%	27,500,693	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 01, 2022	blackrock inc.	8.7%	21,888,278	SC 13G/A
Sep 10, 2021	fmr llc	-	0	SC 13G/A
Feb 16, 2021	price t rowe associates inc /md/	15.2%	39,270,192	SC 13G/A
Feb 10, 2021	vanguard group inc	10.72%	27,548,047	SC 13G/A

HOLX Fair Value

Hologic fair value in different scenarios

The table shows the Fair Value estimates for Hologic for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	70.94 -10.89%	112.01 40.70%	170.55 114.23%	262.85 230.17%	345.42 333.89%
Current Inflation	64.93 -18.44%	100.54 26.29%	149.78 88.14%	227.64 185.94%	296.99 273.06%
Very High Inflation	57.49 -27.79%	86.68 8.88%	125.33 57.43%	186.82 134.67%	241.28 203.08%

Historical Hologic Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Hologic

View All Filings

Date Filed	Form Type	Document
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 10, 2023	8-K	Current Report
Mar 03, 2023	4	Insider Trading

Latest Insider Trading transactions for HOLX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-09	GARRETT SCOTT T	acquired	-	-	1,465	-
2023-03-09	Nawana Namal	acquired	-	-	1,465	-
2023-03-09	Dockendorff Charles J	acquired	-	-	1,465	-
2023-03-09	Stamoulis Christiana	acquired	-	-	1,465	-
2023-03-09	CRAWFORD SALLY	acquired	-	-	1,465	-
2023-03-09	Stewart Stacey D.	acquired	-	-	1,465	-
2023-03-09	HANTSON LUDWIG	acquired	-	-	1,465	-
2023-03-09	Wendell Amy McBride	acquired	-	-	1,465	-
2023-03-01	Anderson Erik S	sold (taxes)	-30,121	79.06	-381	div. pres., breast & skeletal
2023-02-07	Dockendorff Charles J	gifted	-	-	-1,336	-

About Hologic

Stephen P. MacMillan

www.hologic.com

6700

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HOLX Income Statement

2022-12-31

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 25, 2021
Revenues:
Product	$ 886.3	$ 1,303.3
Service and other	187.9	167.8
Revenues	1,074.2	1,471.1
Costs of revenues:
Product	296.2	318.1
Amortization, Cost of Goods Sold	55.6	74.9
Service and other	104.5	91.8
Gross profit	617.9	986.3
Operating expenses:
Research and development	74.8	72.8
Selling and marketing	163.5	147.4
General and administrative	108.5	117.9
Amortization of acquired intangible assets	7.6	10.8
Contingent consideration - fair value adjustment	0.0	(4.1)
Restructuring charges	1.1	0.2
Operating expenses	355.5	345.0
Income from operations	262.4	641.3
Interest income	20.6	0.5
Interest expense	(28.1)	(25.7)
Debt extinguishment loss	0.0	(0.7)
Other income (expense), net	(15.8)	6.5
Income before income taxes	239.1	621.9
Provision for income taxes	51.7	122.7
Net income	$ 187.4	$ 499.2
Net income per common share:
Basic (in usd per share)	$ 0.76	$ 1.97
Diluted (in usd per share)	$ 0.75	$ 1.95
Weighted average number of shares outstanding:
Basic (in shares)	247,319	253,499
Diluted (in shares)	249,281	256,070

HOLX Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Sep. 24, 2022
Current assets:
Cash and cash equivalents	$ 2,441.3	$ 2,339.5
Accounts receivable, less reserves	673.8	617.6
Inventories	677.7	623.7
Prepaid Expense, Current	197.3	232.2
Prepaid Income Taxes-Current	31.1	49.0
Total current assets	4,021.2	3,862.0
Property, plant and equipment, net	494.3	481.6
Intangible assets, net	1,255.4	1,280.6
Goodwill	3,289.6	3,236.5
Other assets	229.8	210.5
Total assets	9,290.3	9,071.2
Current liabilities:
Current portion of long-term debt	20.6	15.0
Accounts payable	201.8	197.7
Accrued expenses	539.0	535.3
Deferred revenue	191.6	186.5
Finance lease obligations	3.2	3.2
Total current liabilities	956.2	937.7
Long-term debt, net of current portion	2,806.2	2,808.4
Finance lease obligations, net of current portion	17.7	18.0
Deferred Income Tax Liabilities, Net	71.7	90.8
Deferred revenue, net of current portion	10.9	9.4
Other long-term liabilities	335.1	330.7
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0.0	0.0
Common stock, $0.01 par value – 750,000 shares authorized; 299,485 and 298,533 shares issued, respectively	3.0	3.0
Additional paid-in-capital	6,060.6	6,042.6
Retained earnings	1,787.7	1,600.3
Treasury stock, at cost – 52,940 and 51,401 shares, respectively	(2,631.5)	(2,531.5)
Accumulated other comprehensive loss	(127.3)	(238.2)
Total stockholders’ equity	5,092.5	4,876.2
Total liabilities and stockholders’ equity	$ 9,290.3	$ 9,071.2